Drug Trial Radar · NCT04435626
Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%
Last checked: Nov 19, 2026Latest source record: Aug 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6,016
Actual
Start
Sep 14, 2020
Primary completion
May 15, 2024
Study completion Jun 14, 2024
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Jun 17, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effect of finerenone compared to placebo (a tablet without active substance) in the reduction of cardiovascular death (generally meaning death due to disease of the heart or blood vessels) and total Heart Failure (HF) events, including HF hospitalization and urgent visits for HF(generally meaning a hospital stay or urgent presentation to a healthcare unit due to worsening symptoms of heart failure) in patients suffering from HF with an ejection fraction greater than or equal to 40%. Researchers will also collect information on how much the heart disease has impact on patient's lives, change of kidney function, and how well finerenone treatment is tolerated. The study plans to enroll 6000 male and female patients of the age of 40 years and above suffering from heart failure with ejection fraction greater than or equal to 40%. Participants will take the study product as oral tablet with a dose between 0 (Placebo) 40 mg once daily. Study duration will be up to 43 months.
Conditions
- Heart Failure
Interventions
Finerenone (BAY94-8862)Drug
For participants with an eGFR ≤60 mL/min/1.73 m\^2: Starting dose is 10 mg OD and maximum dose 20 mg OD. For participants with an eGFR \>60 mL/min/1.73 m\^2: Starting dose is 20 mg OD and maximum dose 40 mg OD. Finerenone is administered orally as immediate release tablets.
PlaceboOther
Placebo tablets matching BAY94-8862 are administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of the Composite Endpoint of Cardiovascular Death and Total (First and Recurrent) Heart Failure EventsTime frame: From randomization up until the end of study, with an average study duration of 32 months
- Occurrence of the Composite Endpoint of Cardiovascular Death and Total (First and Recurrent) Heart Failure EventsTime frame: From randomization up until the end of study, with an average study duration of 32 months
Locations
661 sites in 37 countries. Site status is shown where the registry gives one.
Cardiology, PC
Birmingham, Alabama
Eastern Shore Research Institute, LLC | Fairhope, AL
Fairhope, Alabama
Mobile Heart Specialists - Providence
Mobile, Alabama
University of Arizona Clinical and Translational Sciences Research Center
Tucson, Arizona
Heart Clinic Arkansas
Little Rock, Arkansas
WestSide Medical
Beverly Hills, California
CA Heart and Vein Specialists
Huntington Beach, California
UCI Medical Center - Neurology
Orange, California
Sutter Medical Center - Cardiology
Sacramento, California
NorthBay Clinical Research, LLC | Santa Rosa, CA
Santa Rosa, California
The Lundquist Institute - Gynecology
Torrance, California
Blue Coast Research Center, LLC
Vista, California
Interventional Cardio Medical- DCT Department
West Hills, California
Interventional Cardiology Medical Group | West Hills, CA
West Hills, California
VA Eastern Colorado Health Care System
Aurora, Colorado
Colorado Springs Cardiology - Woodmen Medical Plaza
Colorado Springs, Colorado
South Denver Cardiology Associates, PC
Littleton, Colorado
Cardiovascular & Vein Center of Florida | Bradenton, FL
Bradenton, Florida
Nova Clinical Research - Blake Medical Center
Bradenton, Florida
Cardiology Associates Research Company
Daytona Beach, Florida
North Florida Foundation for Research and Education - Clinical Trial Center
Gainesville, Florida
LifeSpring Research Foundation, LLC
Miami, Florida
Southwest Florida Research | Naples, FL
Naples, Florida
East Coast Institute for Research | St. Augustine, FL
Saint Augustine, Florida
Cardiology Partners Clinical Research Institute | Wellington Office
Wellington, Florida
Centricity Research at Talbotton
Columbus, Georgia
Atlanta Heart Specialists - Tucker
Tucker, Georgia
Advocate Illinois Masonic Medical Center - Cardiology
Chicago, Illinois
Advocate Good Samaritan Hospital - Cardiology
Downers Grove, Illinois
Advocate Condell Medical Center
Libertyville, Illinois
Edward Hospital - Main Campus - Cardiology
Naperville, Illinois
Captain James A. Lovell Federal Health Care Center
North Chicago, Illinois
Carle Health Methodist Hospital - Cardiology
Peoria, Illinois
Midwest Cardiovascular Research and Education Foundation | Elkhart, IN
Elkhart, Indiana
Reid Physicians Associates - Cardiology Department
Richmond, Indiana
Kansas Nephrology Research Institute
Wichita, Kansas
Baptist Health Paducah - Cardiology
Paducah, Kentucky
Cardiovascular Associates Research, LLC
Covington, Louisiana
Heart Clinic of Hammond
Hammond, Louisiana
Louisiana Heart Center - Slidell
Slidell, Louisiana
Showing 40 of 661 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.